Plain-English translation of NCT07285850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether the order and timing of two medications—bevacizumab and atezolizumab—matters for treating advanced liver cancer in patients with fatty liver disease. Half of the participants will receive the medications one after the other (sequential), while the other half will receive them at the same time (concurrent). The study will measure how well each approach works and how your body's immune system responds.
Advanced liver cancer is difficult to treat, especially when patients also have fatty liver disease. Doctors want to understand whether giving these two medications in different sequences might improve outcomes or reduce side effects, and whether understanding changes in your immune system might help predict who benefits most from this treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive the two medications either sequentially (one after the other) or concurrently (at the same time) for up to 6 months. During this time, you will have regular clinic visits for blood tests, imaging scans, and check-ups. You will also have liver biopsies to help doctors understand how the treatment is affecting your tumor's environment. Researchers will closely monitor you for any side effects and ask about your symptoms throughout the study and follow-up period.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China